Anti-Angiogenesis Drug Discovery and Development

Volume 3

by

Atta-ur-Rahman, FRS , M. Iqbal Choudhary

DOI: 10.2174/97816810815571160301
eISBN: 978-1-68108-155-7, 2016
ISBN: 978-1-68108-156-4
ISSN: 2452-3240 (Print)
ISSN: 2210-268X (Online)



Recommend this eBook to your Library

Indexed in: EBSCO, Ulrich's Periodicals Directory.

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pr...[view complete introduction]

Table of Contents

Preface

- Pp. i-iii (3)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

List of Contributors

- Pp. iv-v (2)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

Beta-Blocker Therapy for Retinopathy of Prematurity

- Pp. 3-15 (13)

Imad R. Makhoul, Tatiana Smolkin and David Warburton

View Abstract Purchase Chapter

Disintegrin-Based, Synthetic Cyclic KTS Peptides as Novel Dual Antagonists of α1β1/α2β1 Integrins with Antiangiogenic Activity

- Pp. 16-45 (30)

Tatjana Momic, Jehoshua Katzehendler, Efrat Noy, Hanoch Senderowitz, Johannes A. Eble, Cezary Marcinkiewicz and Philip Lazarovici

View Abstract Purchase Chapter

Current Status of Anti-Angiogenic Therapy in the Clinical Management of Lung Cancer

- Pp. 49-69 (21)

Peter M. Ellis and Abdulaziz Al Farsi

View Abstract Purchase Chapter

Angiogenesis in Hepatocellular Carcinoma (HCC) and its Potential Applications in the Development of Anti-HCC Drugs

- Pp. 97-174 (78)

Guang-Chun Sun, Dai-Wei Zhao, Xu Yang and Lichun Sun

View Abstract Purchase Chapter

Bevacizumab for Glioblastoma Treatment: Reviewing Biological and Clinical Hypothesis for its Success and Failures

- Pp. 175-226 (52)

Ana C. Fernandes, Cláudia Caeiro, Vera Miranda-Gonçalves, Fernanda Cury, Margarida Damasceno, Rui M. Reis and Olga Martinho

View Abstract Purchase Chapter

Subject Index

- Pp. 227-240 (14)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

Preface

Angiogenesis is a normal process for healing and reproduction. It involves the growth of new capillary blood vessels from the pre-existing vessels. However, in disease states angiogenesis leads to abnormal blood vessel growth. This then becomes the underlying process for many deadly diseases, including cancers and retinopathy. Pharmaceutical R&D is currently focused on devising strategies to target biochemical and cellular events involved in the angiogenesis in search of treatment of various diseases. An important approach has been to inhibit the action of various enzymes and factors involved in the complex cascade of reactions leading to new blood vessel formation.

The 3rd volume of the book series “Anti-Angiogenesis Drug Discovery and Development” is a compilation of five excellent reviews, written by leading researchers in these fields. Each review is focused on a certain important aspect of angiogenesis and the modulation of the angiogenesis process through chemotherapeutic agents as possible treatments of various diseases.

Makhouli et al. have contributed a review on various clinical and pre-clinical trials on beta-blockers, such as catecholamine, for the treatment of retinopathy of prematurity (ROP). ROP is a disease of premature babies, which involves abnormal blood vessel formation in the retina. This growth can cause the retina to detach from the back of the eye, leading to complete blindness. The diseases range from being mild to severe and currently no treatment is available. The authors have summarized the results of various clinical and preclinical studies of oral propranolol treatment, and evaluated the efficacy and safety of such treatment at various stages of ROP. Propranolol is used in the treatment of tremors hypertension (high blood pressure), heart rhythm disorders, angina (chest pain), and in other heart or circulatory disorders. It is also used to prevent heart attack, and reduce the severity and frequency of migraine headaches. The use of propranolol in ROP is an important step forward, as well as an example of drug repurposing.

Integrins represent a family of adhesion receptor proteins involved in angiogenesis. The review contributed by Lazarovici et al. is focused on the development of antagonists (disintegrins) of various types of integrins for therapeutic purposes. Obtustatin and viperistatin, two members of the disintegrin protein family, have been used as templates for the synthesis of two linear and cyclic peptides, containing the KTS binding motif. More specifically, two synthetic cyclic linear peptides, vimocin and vidapin, have attracted major scientific interests as dual antagonists of α1/α2 integrins. In vitro and in vivo studies indicated their high potency in inhibiting the adhesion of integrins, thus slowing down the angiogenesis induced by vascular endothelial growth factors. The results of various studies, including stability, potency, efficacy, computational modeling, etc. indicate the promising nature of vimocin and vidapin.

The last three reviews are focused on the therapeutic potential of various antiangiogenic drug candidates in the treatment of cancers, such as lung cancer, hepatocellular carcinoma, and glioblastoma. All three reviews start with the detail descriptions of the role of angiogenesis in tumor progression, and molecular events in angiogenic process, followed by the development of various anti-angiogenic compounds to inhibit the angiogenesis cascade as potential drugs. The results of animal studies and clinical trials present a mixed picture, which demands further studies in this field.

Ellis and Al Farsi review the current status of antiangiogenic therapy in the treatment of lung cancer, known for very high level of angiogenic activity, aggressive nature, and very low survival rate. Antiangiogenic drugs can offer a better therapeutic option for lung cancer, and thus vigorous research is being conducted on this class of potential drugs. The authors have exhaustively reviewed the results of clinical studies on various combinations of therapeutic agents i.e. antiangiogenic monoclonal antibody bevacizumab and various classes of anti-cancer drugs, on the improvement of survival, disease progression, tumor recurrence, and metastasis in NSCLC (Non-small cell lung cancer) patients. The results of these studies were found to be non-conclusive, though some improvement in survival rate has been noted. The authors present a strong case in favor of further studies in the identification of biomarkers, as well as additional translational research.

Hepatocellular carcinoma (HCC) is the most malignant tumor with a very high mortality rate. Available treatment options are few, and far from ideal. HCC is known for the high level of neo-angiogenesis. A series of angiogenic factors have been identified in HCC as possible targets for anti-angiogenic drug discovery. Recently, several anti-agiogenic agents were developed, and extensive animal studies and clinical trials have been conducted. The review, contributed by Sun et al., describes the salient features of various clinical and pre-clinical studies, as well as limitation, challenges, and recent advances in the possible treatment of HCC by anti-angiogenic agents, and their combinations with classical anti-HCC drugs.

The last review of this volume, contributed by Martinho et al., focuses on the treatment of glioblastoma multiforme (GBM) by an FDA approved anti-angiogenic monoclonal antibody, bevacizumab. The results of clinical trials on bevacizumab in combination with radiotherapy and the anti-cancer drug temozolomide (TMZ) have shown improved survival rate in GBM patients. However, data about the quality of life, and functional improvements are conflicting. Reports of adverse effects of bevacizumab further complicate the situation. This requires a better understanding of the biology and mechanism of the angiogenic process involved the in progression of GBM, and improved clinical study design.

We wish to express our gratitude to all the eminent contributors for the timely submission of their articles which have resulted in this excellent 3rd volume of the eBook series volume in this important field. It is the result of efficient coordination and excellent management of the entire team of Bentham Science Publishers. We would like to appreciate the joint efforts of Mr. Omer Shafi (Assistant Manager Publications), Mr. Shehzad Naqvi (Manager Publications) and team leader Mr. Mahmood Alam (Director Publications). We sincerely hope that this volume will receive wide appreciation from the readers.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK
&
M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan

List of Contributors

Editor(s):
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
UK


M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan




Contributor(s):
Abdulaziz Al Farsi
Staff Medical Oncologist
Juravinski Cancer Centre
Hamilton, Ontario
Canada
/
Clinical Research Fellow in Lung Cancer
Department of Oncology, McMaster University
Hamilton, Ontario
Canada


Ana C. Fernandes
Department of Oncology
Centro Hospitalar S. João
Porto
Portugal


Cezary Marcinkiewicz
Department of Bioengineering
College of Engineering, Temple University
Philadelphia, Pennsylvania
USA


Cláudia Caeiro
Department of Oncology
Centro Hospitalar S. João
Porto
Portugal


Dai-Wei Zhao
Department of Surgery
The Second Affiliated Hospital of Guiyang Medical University
3 Kang-Fu Rd., Kaili 556000
China


David Warburton
Children's Hospital Los Angeles, The Haim Saban Research Institute, Developmental Biology and Regenerative Medicine Program
Keck School of Medicine and Ostrow School of Dentistry University of Southern California
Los Angeles, CA
USA


Efrat Noy
Department of Chemistry
Bar Ilan University
Ramat-Gan
Israel


Fernanda Cury
Molecular Oncology Research Center
Barretos Cancer Hospital
Barretos, Sao Paulo
Brazil


Guang-Chun Sun
Department of Pharmacy
The Fifth People’s Hospital of Shanghai, Fudan University
801 He-Qing Rd., Shanghai 200240
China


Hanoch Senderowitz
Department of Chemistry
Bar Ilan University
Ramat-Gan
Israel


Imad R. Makhoul
Department of Neonatology, Ruth Rappaport Children’s Hospital
Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion – Israel Institute of Technology
Haifa
Israel


Jehoshua Katzehendler
School of Pharmacy
Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem
Jerusalem
Israel


Johannes A. Eble
Institute for Physiological Chemistry and Pathobiochemistry
University of Münster
Münster
Germany


Lichun Sun
Department of Pharmacy
The Fifth People’s Hospital of Shanghai, Fudan University
801 He-Qing Rd., Shanghai 200240
China.
/
Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study
Institute of Pharmacy & Pharmacology, University of South China
Hengyang, 421001
China.
/
Department of Medicine, School of Medicine
Tulane University Health Sciences Center
New Orleans, LA 70112-2699
USA


Margarida Damasceno
Department of Oncology
Centro Hospitalar S. João
Porto
Portugal


Olga Martinho
Life and Health Sciences Research Institute (ICVS)
School of Health Sciences, University of Minho
Braga
Portugal.
/
ICVS/3B’s - PT Government Associate Laboratory
Braga/Guimarães
Portugal.
/
Molecular Oncology Research Center
Barretos Cancer Hospital
Barretos, Sao Paulo
Brazil


Peter M. Ellis
Department of Oncology
McMaster University
Hamilton, Ontario
Canada


Philip Lazarovici
School of Pharmacy
Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem
Jerusalem
Israel


Rui M. Reis
Life and Health Sciences Research Institute (ICVS)
School of Health Sciences, University of Minho
Braga
Portugal.
/
ICVS/3B’s - PT Government Associate Laboratory
Braga/Guimarães
Portugal.
/
Molecular Oncology Research Center
Barretos Cancer Hospital
Barretos, Sao Paulo
Brazil


Tatiana Smolkin
Department of Neonatology, Ruth Rappaport Children’s Hospital
Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion – Israel Institute of Technology
Haifa
Israel


Tatjana Momic
School of Pharmacy
Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem
Jerusalem
Israel


Vera Miranda-Gonçalves
Life and Health Sciences Research Institute (ICVS)
School of Health Sciences, University of Minho
Braga
Portugal.
/
ICVS/3B’s - PT Government Associate Laboratory
Braga/Guimarães
Portugal


Xu Yang
Department of Pharmacy
The Fifth People’s Hospital of Shanghai, Fudan University
801 He-Qing Rd., Shanghai 200240
China




Advertisement



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science